{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:57:58Z","timestamp":1782226678042,"version":"3.54.5"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific & Industrial Research","doi-asserted-by":"publisher","award":["111-2536-319\/2K23\/1"],"award-info":[{"award-number":["111-2536-319\/2K23\/1"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/8-4\/15\/Env\/2020-NCD-II"],"award-info":[{"award-number":["5\/8-4\/15\/Env\/2020-NCD-II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bioorg.2024.108017","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T20:56:14Z","timestamp":1733604974000},"page":"108017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Chemotherapeutic potential of radotinib against blood and solid tumors: A beacon of hope in drug repurposing"],"prefix":"10.1016","volume":"154","author":[{"given":"Suryaa","family":"Manoharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekambaram","family":"Perumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.108017_b0005","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.476.476","article-title":"Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia patients: 12 months result of phase 3 clinical trial","volume":"126","author":"Kwak","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.108017_b0010","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/leu.2015.42","article-title":"Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1","volume":"29","author":"Zabriskie","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2024.108017_b0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2024.108017_b0020","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.drudis.2022.02.015","article-title":"Small molecules and their impact in drug discovery: a perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory","volume":"27","author":"Beck","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2024.108017_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2024.108017_b0030","article-title":"Small molecule inhibitors targeting the cancers","volume":"3","author":"Liu","year":"2022","journal-title":"MedComm (Beijing)"},{"key":"10.1016\/j.bioorg.2024.108017_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27207124","article-title":"Molecular recognition of FDA-approved small molecule protein kinase drugs in protein kinases","volume":"27","author":"Zhu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.108017_b0040","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2024.108017_b0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.beha.2009.04.004","article-title":"CML: a model for targeted therapy","volume":"22","author":"Cilloni","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.bioorg.2024.108017_b0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bioorg.2024.108017_b0055","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","article-title":"Chronic myelogenous leukemia: mechanisms underlying disease progression","volume":"16","author":"Shet","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2024.108017_b0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","article-title":"Imatinib and beyond\u2014exploring the full potential of targeted therapy for CML","volume":"6","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0065","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s12185-021-03127-5","article-title":"Current status and novel strategy of CML","volume":"113","author":"Morita","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bioorg.2024.108017_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114442","article-title":"The progress of small-molecules and degraders against BCR-ABL for the treatment of CML","volume":"238","author":"Pan","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108017_b0075","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 \u2013 common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bioorg.2024.108017_b0080","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11899-021-00653-1","article-title":"Treatment-free remission: the new goal in CML therapy","volume":"16","author":"Atallah","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"2014","key":"10.1016\/j.bioorg.2024.108017_b0085","first-page":"2005","article-title":"Synthetic approaches to the 2012 new drugs","volume":"22","author":"Ding","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108017_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106847","article-title":"Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States","volume":"194","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2024.108017_b0095","article-title":"Synthetic approaches for pharmacologically active decorated six-membered diazines, in: Strategies for the synthesis of heterocycles and their spplications","author":"Najajreh","year":"2023","journal-title":"IntechOpen"},{"key":"10.1016\/j.bioorg.2024.108017_b0100","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/ejoc.201500205","article-title":"Gold\u2010catalysed synthesis of exocyclic vinylogous amides and \u03b2\u2010amino ketones: a detailed study on the 5\u2010exo \/6\u2010endo \u2010dig selectivity, methodology and scope","volume":"2015","author":"Scarpi","year":"2015","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.bioorg.2024.108017_b0105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0065-2725(08)60072-0","article-title":"Enaminones in heterocyclic synthesis","author":"Lue","year":"1996","journal-title":"Adv Heterocycl Chem."},{"key":"10.1016\/j.bioorg.2024.108017_b0110","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995\u20132021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108017_b0115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.stem.2012.01.006","article-title":"Hematopoiesis: a human perspective","volume":"10","author":"Doulatov","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bioorg.2024.108017_b0120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s004320050228","article-title":"Chronic myelogenous leukemia: molecular and cellular aspects","volume":"124","author":"Pasternak","year":"1998","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0125","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.108017_b0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40","author":"Sattlermc","year":"2003","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bioorg.2024.108017_b0135","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0145-2126(95)00057-7","article-title":"BCR\/ABL and leukemia","volume":"20","author":"Butturini","year":"1996","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bioorg.2024.108017_b0140","article-title":"Future approaches for treating chronic myeloid leukemia: CRISPR therapy","volume":"10","author":"Vuelta","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.bioorg.2024.108017_b0145","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","article-title":"Chronic myeloid leukemia: beyond BCR-ABL1","volume":"13","author":"Zhou","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.bioorg.2024.108017_b0150","first-page":"117","article-title":"Structure of the Bcr-Abl oncoprotein oligomerization domain","volume":"9","author":"Zhao","year":"2002","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.bioorg.2024.108017_b0155","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1074\/jbc.R112.438382","article-title":"Structure and dynamic regulation of Abl kinases*","volume":"288","author":"Panjarian","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2024.108017_b0160","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1947601912458584","article-title":"Structure regulation, signaling, and targeting of Abl kinases in cancer","volume":"3","author":"Hantschel","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bioorg.2024.108017_b0165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0170","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601912462126","article-title":"The ins and outs of Bcr-Abl inhibition","volume":"3","author":"Reddy","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bioorg.2024.108017_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25184210","article-title":"Bcr-Abl allosteric inhibitors: where we are and where we are going to","volume":"25","author":"Carofiglio","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.108017_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0040144","article-title":"A Src-Like inactive conformation in the Abl tyrosine kinase domain","volume":"4","author":"Levinson","year":"2006","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bioorg.2024.108017_b0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2024.108017_b0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s42003-019-0743-5","article-title":"A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein","volume":"3","author":"Liu","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bioorg.2024.108017_b0195","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.molonc.2013.06.001","article-title":"Through the open door: Preferential binding of dasatinib to the active form of BCR\u2010ABL unveiled by in silico experiments","volume":"7","author":"Laurini","year":"2013","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0200","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2024.108017_b0205","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2024.108017_b0210","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","article-title":"The role of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"18","author":"Kujawski","year":"2007","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bioorg.2024.108017_b0215","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2024.108017_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126758","article-title":"Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants","volume":"29","author":"Yang","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.108017_b0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bioorg.2024.108017_b0230","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cbdd.13801","article-title":"Recent advances in Bcr\u2010Abl tyrosine kinase inhibitors for overriding T315I mutation","volume":"97","author":"Liu","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2024.108017_b0235","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620717719851","article-title":"Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update","volume":"8","author":"Eskazan","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.bioorg.2024.108017_b0240","article-title":"Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL tyrosine kinase inhibitors: radotinib phase 2 clinical trial","volume":"120","author":"Kim","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.108017_b0245","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"23","author":"Kwak","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.108017_b0250","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3086.3086","article-title":"Impact of body weight adjusted dose on efficacy and safety of radotinib in chronic myeloid leukemia","volume":"128","author":"Noh","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.108017_b0255","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/cam4.1436","article-title":"Determination of a radotinib dosage regimen based on dose\u2013response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia","volume":"7","author":"Noh","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.bioorg.2024.108017_b0260","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bjh.16381","article-title":"Long\u2010term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)","volume":"189","author":"Do","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bioorg.2024.108017_b0265","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2017.03.040","article-title":"Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells","volume":"804","author":"Heo","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.108017_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129853","article-title":"Radotinib induces apoptosis of CD11b+ cells differentiated from acute myeloid leukemia cells","volume":"10","author":"Heo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2024.108017_b0275","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejphar.2016.07.049","article-title":"Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors","volume":"789","author":"Heo","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.108017_b0280","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc989","article-title":"Disruption of differentiation in human cancer: AML shows the way","volume":"3","author":"Tenen","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2024.108017_b0285","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2024.108017_b0290","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15492-5","article-title":"Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death","volume":"7","author":"Heo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2024.108017_b0295","doi-asserted-by":"crossref","DOI":"10.1177\/1010428319848612","article-title":"Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression","volume":"41","author":"Heo","year":"2019","journal-title":"Tumor Biol."},{"key":"10.1016\/j.bioorg.2024.108017_b0300","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1186\/s12885-020-07701-8","article-title":"Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death","volume":"20","author":"Heo","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2024.108017_b0305","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2162-3619-2-20","article-title":"Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia","volume":"2","author":"Momparler","year":"2013","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0310","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094955","article-title":"Inhibitors of chemoresistance pathways in combination with Ara-C to overcome multidrug resistance in AML. A mini review","volume":"22","author":"Fajardo-Ordu\u00f1a","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.108017_b0315","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-23321-6","article-title":"CISNE: an accurate description of dose-effect and synergism in combination therapies","volume":"8","author":"Garc\u00eda-Fuente","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2024.108017_b0320","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-92651-9","article-title":"The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway","volume":"11","author":"Heo","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2024.108017_b0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265958","article-title":"Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling","volume":"17","author":"Heo","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2024.108017_b0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9580561","article-title":"Novel application of radotinib for the treatment of solid tumors via natural killer cell activation","volume":"2018","author":"Kim","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bioorg.2024.108017_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2024.108017_b0340","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.cdd.4401179","article-title":"Signaling and transcriptional control of Fas ligand gene expression","volume":"10","author":"Kavurma","year":"2003","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioorg.2024.108017_b0345","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","article-title":"The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson\u2019s disease mouse model","volume":"27","author":"Lee","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bioorg.2024.108017_b0350","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2024.108017_b0355","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40360-022-00634-x","article-title":"Radotinib attenuates TGF\u03b2 -mediated pulmonary fibrosis in vitro and in vivo: exploring the potential of drug repurposing","volume":"23","author":"Baek","year":"2022","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2024.108017_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512241","article-title":"Radotinib decreases prion propagation and prolongs survival times in models of prion disease","volume":"24","author":"Choi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.108017_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2023.101278","article-title":"In-silico study for the identification of potential destabilizers between the spike protein of SARS-CoV-2 and human ACE-2","volume":"40","author":"Medina-Barandica","year":"2023","journal-title":"Inform. Med. Unlocked"},{"key":"10.1016\/j.bioorg.2024.108017_b0370","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-08073-8","article-title":"Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing","volume":"12","author":"Mosharaf","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2024.108017_b0375","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000501537","article-title":"Systematic review and meta-analysis of new-generation tyrosine kinase inhibitors versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"143","author":"Pan","year":"2020","journal-title":"Acta Haematol."},{"key":"10.1016\/j.bioorg.2024.108017_b0380","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6039-9","article-title":"Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis","volume":"19","author":"Tang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2024.108017_b0385","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.clml.2016.03.003","article-title":"Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups: a systematic review and meta-analysis of eight randomized trials","volume":"16","author":"Yun","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.bioorg.2024.108017_b0390","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2217\/fon-2022-1008","article-title":"Rash with different types of BCR-ABL inhibitors in chronic myelogenous leukemia: a systematic review and meta-analysis","volume":"19","author":"Li","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0395","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/0284186X.2023.2263152","article-title":"Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis","volume":"62","author":"Cha","year":"2023","journal-title":"Acta Oncol. (Madr)"},{"key":"10.1016\/j.bioorg.2024.108017_b0400","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/bcp.13933","article-title":"Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta\u2010analysis","volume":"85","author":"Fachi","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.108017_b0405","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2013.096776","article-title":"Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors","volume":"99","author":"Kim","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2024.108017_b0410","article-title":"Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2024.108017_b0415","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2024.108017_b0420","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/cdd.2011.23","article-title":"Abl interconnects oncogenic Met and p53 core pathways in cancer cells","volume":"18","author":"Furlan","year":"2011","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioorg.2024.108017_b0425","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1158\/0008-5472.CAN-06-0734","article-title":"Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells","volume":"66","author":"Srinivasan","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.108017_b0430","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/sj.onc.1210714","article-title":"Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival","volume":"27","author":"Srinivasan","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2024.108017_b0435","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/0008-5472.CAN-16-1378","article-title":"Cervical cancer growth is regulated by a c-ABL\u2013PLK1 signaling axis","volume":"77","author":"Yang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.108017_b0440","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1038\/onc.2008.86","article-title":"Activated c-Abl tyrosine kinase in malignant solid tumors","volume":"27","author":"Lin","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2024.108017_b0445","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00345-011-0767-z","article-title":"Tyrosine kinase expression profile in clear cell renal cell carcinoma","volume":"30","author":"Behbahani","year":"2012","journal-title":"World J. Urol."},{"key":"10.1016\/j.bioorg.2024.108017_b0450","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1368-8375(99)00067-6","article-title":"c-Abl expression in oral squamous cell carcinomas","volume":"36","author":"Yanagawa","year":"2000","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0455","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2013.06.031","article-title":"Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer","volume":"131","author":"Zhou","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0460","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1097\/01.ju.0000158448.56888.09","article-title":"renal medullary carcinoma and ABL gene amplification","volume":"173","author":"Simpson","year":"2005","journal-title":"J. Urol."},{"key":"10.1016\/j.bioorg.2024.108017_b0465","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11523-008-0101-x","article-title":"Imatinib in the treatment of solid tumours","volume":"4","author":"Duffaud","year":"2009","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0470","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/annonc\/mdx079","article-title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","volume":"28","author":"Guo","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0475","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/annonc\/mdr598","article-title":"Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib","volume":"23","author":"Reichardt","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0480","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ctrv.2010.02.015","article-title":"Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors","volume":"36","author":"Araujo","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2024.108017_b0485","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1172\/JCI32373","article-title":"An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic","volume":"117","author":"Fern\u00e1ndez","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bioorg.2024.108017_b0490","article-title":"Re-engineering dasatinib into an immuno-synergic","author":"Fern\u00e1ndez","year":"2018","journal-title":"Drug"},{"key":"10.1016\/j.bioorg.2024.108017_b0495","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.canlet.2008.02.025","article-title":"Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells","volume":"265","author":"Tolomeo","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2024.108017_b0500","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041644","article-title":"Caffeic acid enhances the anti-leukemic effect of imatinib on chronic myeloid leukemia cells and triggers apoptosis in cells sensitive and resistant to imatinib","volume":"22","author":"Feriotto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.108017_b0505","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1096\/fj.07-101394","article-title":"Imatinib mesylate\u2010resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol","volume":"22","author":"Puissant","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.bioorg.2024.108017_b0510","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11033-023-09135-4","article-title":"Combination treatments of imatinib with astaxanthin and crocin efficiently ameliorate antioxidant status, inflammation and cell death progression in imatinib-resistant chronic myeloid leukemia cells","volume":"51","author":"Golestani","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bioorg.2024.108017_b0515","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ptr.6233","article-title":"The combined treatment of brassinin and imatinib synergistically downregulated the expression of MMP\u20109 in SW480 colon cancer cells","volume":"33","author":"Bakar-Ates","year":"2019","journal-title":"Phytother. Res."},{"key":"10.1016\/j.bioorg.2024.108017_b0520","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4028\/p-7lk0os","article-title":"Synergistic anticancer activity of cinnamon bark oil and imatinib mesylate combination on colorectal cancer cell lines","volume":"914","author":"Khaing","year":"2022","journal-title":"Key Eng. Mater."},{"key":"10.1016\/j.bioorg.2024.108017_b0525","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.108017_b0530","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: a novel, selective tyrosine kinase inhibitor","volume":"38","author":"Blay","year":"2011","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bioorg.2024.108017_b0535","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/DDDT.S3181","article-title":"Development and targeted use of nilotinib in chronic myeloid leukemia","author":"Jabbour","year":"2008","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2024.108017_b0540","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2024.108017_b0545","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40360-018-0270-x","article-title":"Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents","volume":"19","author":"Ananthula","year":"2018","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2024.108017_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106418","article-title":"Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19","volume":"184","author":"Baalbaki","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2024.108017_b0555","doi-asserted-by":"crossref","first-page":"16981","DOI":"10.1073\/pnas.1905239116","article-title":"Repurposing dasatinib for diffuse large B cell lymphoma","volume":"116","author":"Scuoppo","year":"2019","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824009222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824009222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T02:02:40Z","timestamp":1736474560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824009222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":111,"alternative-id":["S0045206824009222"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108017","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapeutic potential of radotinib against blood and solid tumors: A beacon of hope in drug repurposing","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108017"}}